ME
Therapeutic Areas
Biosidus Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Biosimilar Filgrastim | Neutropenia | Commercial |
| Biosimilar Rituximab | B‑cell Non‑Hodgkin Lymphoma | Commercial |
| Biosimilar Etanercept | Rheumatoid Arthritis | Commercial |
| Biosimilar Trastuzumab | HER2‑Positive Breast Cancer | Commercial |
| Biosimilar Insulin Glargine | Diabetes Mellitus | Phase 3 |
| Biosimilar Darbepoetin Alfa | Anemia of Chronic Kidney Disease | Phase 2 |